Reactions 1704, p277 - 2 Jun 2018 Progressive multifocal leukoencephalopathy: case report A 37-year-old woman developed progressive multifocal leukoencephalopathy (PML) following treatment with natalizumab for multiple sclerosis (MS) [dosage not stated]. The woman had been diagnosed with relapsing-remitting MS at the age of 9 years. She was started on treatment with infusion of natalizumab for 5 years with a satisfactory response. In the summer of 2014, when she was 37 years of age, she developed a progressive right homonymous hemianopia after receiving a total of 58 infusions of natalizumab. An MRI showed JCv-DNA in CSF. Therefore, natalizumab was stopped. On the basis of the clinical and MRI features, the woman was diagnosed with a definite natalizumab-related PML [outcome not stated]. Author comment: "[A] definite [natalizumab]-related PML was diagnosed". Mancinelli CR, et al. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?. Neurological Sciences 39: 965-966, No. 5, May 2018. Available from: URL: http://doi.org/10.1007/ s10072-017-3228-7 - Italy 803323476 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud